Online First »
According to a report from the Office of the Inspector General (OIG) of the Department of Health and Human Services, Medicare's prescription program kept paying for costly medications even after patients were deceased.
Online Exclusive »
After an FDA advisory panel previously called for limited use of edoxaban for atrial fibrillation (AF), the panel ultimately voted in favor of edoxaban for the prevention of stroke and non–central-nervous-system systemic embolism in patients with nonvalvular AF. The FDA is expected to make a final decision in the next few months, and if approved, this would be the fourth novel anticoagulant for the treatment of AF.
Cover Story; American Academy of Pain Management »
Phoenix—As a clinical pharmacy specialist at the Stratton Veterans Affairs Medical Center in Albany, New York, Jeffrey Fudin, PharmD, is prohibited from prescribing or dispensing marijuana. He is a federal government employee and must abide by US law that makes marijuana illegal.
- Improving Men’s Health, Quality of Life, and Cost Outcomes: Evolving Treatment Strategies for Benign Prostatic Hyperplasia
- Building Better COPD Management Programs: Incorporating HEDIS Measures and Clinical Data
- Assessing the Cost/Benefit of Oral MS Therapies on Patient Health and Resource Utilization
- Incorporating HEDIS Measures and Newer Therapies to Improve COPD Treatment Adherence and Outcomes
- Translating Guidelines and Evidence on Newer Anticoagulants to Improved Clinical and Cost Outcomes in AF-Related Stroke
- Opportunities to Reduce the Clinical and Economic Burden of Hyponatremia: Clinical and Pharmacoeconomic Guidance for Managed Care